-
1 Comment
Carna Biosciences, Inc is currently in a long term uptrend where the price is trading 18.4% above its 200 day moving average.
From a valuation standpoint, the stock is 79.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.8.
Carna Biosciences, Inc's total revenue sank by 17.2% to $286M since the same quarter in the previous year.
Its net income has dropped by 62.2% to $-462M since the same quarter in the previous year.
Based on the above factors, Carna Biosciences, Inc gets an overall score of 2/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| ISIN | JP3220550002 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 5B |
|---|---|
| PE Ratio | None |
| Beta | 0.47 |
| Target Price | 3400 |
| Dividend Yield | None |
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, Luciferase PPI stable cell lines, kinase assay kits, peptide substrate, mobility shifty assay, and lipid kinase panels. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection assays. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Sumitomo Pharma, Gilead Sciences. Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4572.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
